Experimental cell therapy tested for Tough-to-Treat blood disorder
NCT ID NCT07075484
Summary
This early-stage study tested the safety and initial effectiveness of a new cell therapy called YTS109 for people with severe autoimmune hemolytic anemia (AIHA) who haven't responded to at least three previous treatments. The trial involved just 7 participants and focused on finding a safe dose while monitoring for side effects and early signs that the therapy might help control the disease. Researchers also explored whether giving the cells without strong immune-suppressing drugs beforehand could work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.